Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00081683" target="_blank" >RIV/65269705:_____/25:00081683 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00140734
Result on the web
<a href="https://link.springer.com/article/10.1007/s00277-025-06228-x" target="_blank" >https://link.springer.com/article/10.1007/s00277-025-06228-x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-025-06228-x" target="_blank" >10.1007/s00277-025-06228-x</a>

Result language
angličtina
Original language name
Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib
Original language description
Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)